Drug intelligence / Profile preview

SY-116

Development stage: Preclinical
Lead developer: Seinda Pharmaceutical
Administration: Ophthalmic, Topical

Overview

SY-116 is an investigational, preclinical-stage drug candidate developed by Seinda Pharmaceutical for ophthalmic applications. It is designed as a topical treatment for immune modulation within the eye. As of current pipeline reports, the specific molecular target and modality (e.g., small molecule or biologic) have not been publicly disclosed by the company. The candidate is part of a broader portfolio at Seinda Pharmaceutical targeting ocular surface and retinal disorders, aiming to provide localized therapeutic effects through immune regulation.

Beyond the preview

Go deeper on SY-116.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-116.

Explore the full profile